PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010 2011 2012
Mbeya referral hospital is the main referral facility providing terciary care in the Southern zone of Tanzania. With these funds Mbeya referral will provide facility based care services which includes intergration of positive prevention services, supporting nutritional assessment and counseling in all supported facilities as well as to improve linkages with other services and facilities in Mbeya region and other Southern zone regions.
Focus on quality HIV services at existing sites and scaling up to cover private hospitals and previously underserved areas. This will be accomplished through regular supportive supervision, clinical and nutrition mentoring, patient monitoring, and ensuring uninterrupted supply of drugs and reagents through central procurement mechanism, capacity building to local partners in financial accountability, technical support, program oversight and M&E. Partner works in Mbeya Referal Hospital for the Southen Zone and currently covers 5,377 patients on treatment. $100,000 additional funds have been moved from PLHA to strengthen integration of peer education (PE) activities within ART services.
These funds are proposed for the following activities: Scale up cotrimoxazole (CTX) prophylaxis for HIV-exposed and infected children; provide nutrition assessment, counseling and support; provide prevention, diagnosis and management of tuberculosis and other opportunistic infections (OI's); provide palliative care and psychosocial support. The funds will be used to improve linkages to Community Based Care including: under 5 child survival interventions and community HIV supported services. These activities will be achieved through training and on-site mentorship, establishment of coordinating committees with community-based organizations, advocacy and community mobilization. These activities will take place in Mbeya Referral Hospital.
These funds are proposed for the following activities: Implement updated WHO treatment guidelines to improve access to pediatric ART, including treatment of all HIV infected children <24 months;enhance the identification and diagnosis of HIV for infants and children through EID, PITC in in-patient and out-patient settings, immunization, OVC, and TB/HIV clinics; improve follow-up services for HIV-exposed infants and children and track and retain children in care and treatment; monitor response and adherence to treatment. These activities will be achieved through training, on-site mentorship, advocacy, community mobilization, and updating of tools for tracking and retention. These activities will take place in Mbeya with the aim of enrolling 197 new children on ART.
Expansion of MC support in Mbeya region. Partner will work with Mbeya RMO to expand MC in Mbeya region.
i. HIV drug resistance testing
($250, 000)
ii. Mentorship of 2 selected district labs for SLMTA @ $10,000 per lab
iii. ISO accreditation for MRH
iv. Training of 4 equipment technician with each technician trained on one specific equipment. One technician from each region except Mbeya region which already has trained equipment technicians ($10,000 per technician)
Maintain services related to implementation of the Three I's. It is estimated that around 20% of new patients enrolling in HIV care would present signs and symptoms of advanced HIV diseases and diagnosing TB among this group is difficult as the routine diagnostic tests (AFB smear microscopy and/or chest X ray) are neither very sensitive nor very specific and undiagnosed TB remains a major cause of mortality in this group. To enhance TB diagnosis in this group, there is a high need of investing in sophisticated TB diagnostic tests e.g. Liquid culture and Line Probe Assays. To increase access to this service, the TB Laboratory in Mbeya Referral Hospital will use MIGT and a Line Probe Assay for patients present in HIV Care with advanced HIV diseases. Services will be provided in Mbeya Referral Hospital and surrounding regions. (Rukwa, Mbeya, Ruvuma, Iringa & Tabora). MIGT and Line Probe Assay reagents at a cost of $ 261,520 will be purchased by SCMS. Clinical SRU agreed that funds for procurement of these reagents will come from SCMS.
